ADAP Stock Overview
A clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adaptimmune Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.68 |
| 52 Week High | US$2.05 |
| 52 Week Low | US$0.42 |
| Beta | 2.25 |
| 11 Month Change | -7.80% |
| 3 Month Change | -44.26% |
| 1 Year Change | 52.43% |
| 33 Year Change | -83.61% |
| 5 Year Change | -46.03% |
| Change since IPO | -96.05% |
Recent News & Updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Shareholder Returns
| ADAP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.8% | 4.0% | 2.2% |
| 1Y | 52.4% | 18.3% | 32.6% |
Return vs Industry: ADAP exceeded the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: ADAP exceeded the US Market which returned 32.6% over the past year.
Price Volatility
| ADAP volatility | |
|---|---|
| ADAP Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ADAP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ADAP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 449 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center.
Adaptimmune Therapeutics plc Fundamentals Summary
| ADAP fundamental statistics | |
|---|---|
| Market cap | US$178.38m |
| Earnings (TTM) | -US$44.52m |
| Revenue (TTM) | US$175.04m |
1.0x
P/S Ratio-3.9x
P/E RatioIs ADAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADAP income statement (TTM) | |
|---|---|
| Revenue | US$175.04m |
| Cost of Revenue | US$143.17m |
| Gross Profit | US$31.87m |
| Other Expenses | US$76.39m |
| Earnings | -US$44.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 18.21% |
| Net Profit Margin | -25.43% |
| Debt/Equity Ratio | 62.3% |
How did ADAP perform over the long term?
See historical performance and comparison